Clinical Trial

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT07134998
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced KRAS G12D Mutant Solid Tumors
Enrollment 153 participants
Start Date 2025-09-16
Primary Completion 2028-05 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-05